Acquired Company
VBI Vaccines was acquired by K2 VBI Equity Trust, LLC on January 3, 2025.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company is headquartered in Cambridge, Massachusetts. Show more
160 SECOND STREET, CAMBRIDGE, MA, UNITED STATES, 02142, USA
Market Cap
1.873M
52 Wk Range
$0.00 - $0.00
Previous Close
$0.07
Open
$0.07
Volume
N/A
Day Range
$0.07 - $0.07
Enterprise Value
0.00
Cash
12.6M
Avg Qtr Burn
-11.77M
Insider Ownership
6.77%
Institutional Own.
13.04%
Qtr Updated
03/31/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
PreHevbrio (Sci-B-Vac®) Details Hepatitis B, Hepatitis B vaccine, Pain | Approved Quarterly sales | |
VBI-1901 (eVLP) Details Glioblastoma, Cancer | Phase 2b Data readout | |
VBI-2601 (BRII-179) combo w/ PEG-IFNα Details Chronic hepatitis B, Hepatitis B | Phase 2 Update | |
VBI-2902 Details COVID-19 | Phase 1/2 Data readout | |
VBI-2905 Details COVID-19 | Phase 1/2 Update | |
VBI-2901 Details COVID-19 | Phase 1 Data readout | |
VBI-1501 Details Cytomegalovirus | Phase 1 Update |
